NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States

Cancer

Volumn 122, Issue 7, 2016, Pages 1097-1107

  Prasad, Manju L ^a   Vyas, Monika ^a   Horne, Matthew J ^a   Virk, Renu K ^a   Morotti, Raffaella ^a   Liu, Zongzhi ^a   Tallini, Giovanni ^b   Nikiforova, Marina N ^c   Christison Lagay, Emily R ^a   Udelsman, Robert ^a   Dinauer, Catherine A ^a   Nikiforov, Yuri E ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

neurotrophic tyrosine kinase; papillary thyroid carcinoma; pediatric cancer; receptor type 3 ets variant 6 (NTRK3 ETV6) fusion oncogene; thyroid neoplasms

Indexed keywords

B RAF KINASE; PROTEIN PATCHED 1; TRANSCRIPTION FACTOR ETV6; BRAF PROTEIN, HUMAN; NEUROTROPHIN 3 RECEPTOR; NUCLEOPORIN; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE A; REPRESSOR PROTEIN; RET PROTEIN, HUMAN; TPR PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

ADOLESCENT; ADULT; ARTICLE; BRAF GENE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ETV6 GENE; FEMALE; FUSION GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LYMPH VESSEL METASTASIS; MALE; NTRK1 GENE; NTRK3 GENE; ONCOGENE RET; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PTC1 GENE; PTC3 GENE; THYROID CARCINOMA; TPR GENE; UNITED STATES; CARCINOMA; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR;

ADOLESCENT; CARCINOMA; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MUTATION; NEW ENGLAND; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, TRKA; RECEPTOR, TRKC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 84955619238     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29887     Document Type: Article

References (41)

1. Siegel DA, King J, Tai E, et al., Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009 [serial online]. Pediatrics. 2014; 134: e945-e955.
2. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159: 676-690.
3. Soares P, Trovisco V, Rocha AS, et al., BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22: 4578-4580.
4. Cohen Y, Xing M, Mambo E, et al., BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95: 625-627.
5. Kimura ET, Nikiforova MN, Zhu Z, et al., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454-1457.
6. Lemoine NR, Mayall ES, Wyllie FS, et al., Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988; 48: 4459-4463.
7. Suarez HG, Du Villard JA, Caillou B, et al., Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene. 1988; 2: 403-406.
8. Grieco M, Santoro M, Berlingieri MT, et al., PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60: 557-563.
9. Pierotti MA, Bongarzone I, Borrello MG, et al., Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Invest. 1995; 18: 130-133.
10. Pierotti MA, Vigneri P, Bongarzone I,. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998; 154: 237-247.
11. Nikiforov YE, Nikiforova MN,. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011; 7: 569-580.
12. Niemeier LA, Kuffner Akatsu H, Song C, et al., A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012; 118: 2069-2077.
13. Xing M, Alzahrani AS, Carson KA, et al., Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015; 33: 42-50.
14. Adeniran AJ, Zhu Z, Gandhi M, et al., Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006; 30: 216-222.
15. Finkelstein A, Levy GH, Hui P, et al., Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology. 2012; 60: 1052-1059.
16. Penko K, Livezey J, Fenton C, et al., BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid. 2005; 15: 320-325.
17. Rosenbaum E, Hosler G, Zahurak M, et al., Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol. 2005; 18: 898-902.
18. Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP,. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma [serial online]. Laryngoscope. 2014; 124: E389-E393.
19. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA,. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57: 1690-1694.
20. Fenton CL, Lukes Y, Nicholson D, et al., The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab. 2000; 85: 1170-1175.
21. Kumagai A, Namba H, Saenko VA, et al., Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab. 2004; 89: 4280-4284.
22. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al., Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013; 123: 4935-4944.
23. Bongarzone I, Fugazzola L, Vigneri P, et al., Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996; 81: 2006-2009.
24. Ito T, Seyama T, Iwamoto KS, et al., In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 1993; 53: 2940-2943.
25. Fugazzola L, Pilotti S, Pinchera A, et al., Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995; 55: 5617-5620.
26. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM,. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995; 11: 2459-2467.
27. Thomas GA, Bunnell H, Cook HA, et al., High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999; 84: 4232-4238.
28. Leeman-Neill RJ, Kelly LM, Liu P, et al., ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2014; 120: 799-807.
29. Leeman-Neill RJ, Brenner AV, Little MP, et al., RET/PTC and PAX8/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013; 119: 1792-1799.
30. Ganly I, Wang L, Tuttle RM, et al., Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol. 2015; 46: 657-664.
31. Adeniran AJ, Hui P, Chhieng DC, et al., BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol. 2011; 55: 570-575.
32. Rhoden KJ, Johnson C, Brandao G, et al., Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab Invest. 2004; 84: 1557-1570.
33. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE,. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013; 98: E1852-E1860.
34. Nikiforov YE, Carty SE, Chiosea SI, et al., Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014; 120: 3627-3634.
35. The R Project for Statistical Computing. R-3.1.1 for Windows. Available at: https://cran.r-project.org/bin/windows/base/old/3.1.1/. Accessed April 21, 2014.
36. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer: Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2010.
37. Nikiforova MN, Stringer JR, Blough R, et al., Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000; 290: 138-141.
38. Roccato E, Bressan P, Sabatella G, et al., Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 2005; 65: 2572-2576.
39. Ivanova R, Soares P, Castro P, Sobrinho-Simoes M,. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch. 2002; 440: 418-424.
40. Memorial Sloan-Kettering Cancer Center. cBioPortal for Cancer Genomics. Available at: www.cbioportal.org/study.do?cancer-study-id=thca-tcga. Accessed August 1, 2015.
41. Zhang Y, Chen Y, Huang H, et al., Diagnostic radiography exposure increases the risk for thyroid microcarcinoma: a population-based case-control study. Eur J Cancer Prev. 2015; 24: 439-446.